Cocrystal Pharma (NASDAQ:COCP) Shares Down 5.6% – Here’s What Happened

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s share price dropped 5.6% during trading on Wednesday. The company traded as low as $1.01 and last traded at $1.01. 22,815 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 35,181 shares. The stock had previously closed at $1.07.

Analyst Upgrades and Downgrades

COCP has been the subject of several recent analyst reports. Weiss Ratings downgraded Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright restated a “buy” rating on shares of Cocrystal Pharma in a report on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Cocrystal Pharma Trading Down 5.6%

The firm has a 50-day moving average of $1.10 and a 200-day moving average of $1.10. The stock has a market capitalization of $19.45 million, a price-to-earnings ratio of -1.33 and a beta of 1.60.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million. On average, equities research analysts anticipate that Cocrystal Pharma, Inc. will post -0.69 EPS for the current year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company uses structure-based drug discovery and advanced medicinal chemistry to design small-molecule treatments intended to target viral replication mechanisms.

Cocrystal’s research and development programs have focused primarily on infectious diseases, including influenza A and norovirus. Its pipeline has included orally administered antiviral candidates designed to inhibit viral polymerase proteins, as well as programs addressing other significant viral pathogens.